Leuven Dose-Dense Paclitaxel/Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma
Leuven Dose-Dense Paclitaxel/Carboplatin Regimen in Patients With Primary Advanced or Recurrent Endometrial Carcinoma
复制标题
DOI：
10.1111/igc.0b013e3181ad3dcb
复制
发表时间：
2009-08-01
影响因子：
4.8
通讯作者：
Amant, Frederic
中科院分区：
文献类型：
--
作者：
Vandenput, Ingrid;Vergote, Ignace;Amant, Frederic
目的：评估剂量密集的紫杉醇/卡铂（TC）原发性晚期或复发性子宫内膜癌患者的反应。方法：每 3 周在第 1 天和第 8 天给予 6 个疗程的紫杉醇 (90 mg/m(2)) 和卡铂（曲线下面积，4）。根据实体瘤疗效评价标准评价疗效。结果：42例患者接受了剂量密集TC治疗。中位年龄为 63.9 岁（范围：41-81 岁）。主要的组织病理学类型是浆液性/透明细胞型（n = 27）和子宫内膜样型（n = 13）。患者被分为 2 组：初治组（n = 28，第 1 组）和既往化疗组（n = 14，第 2 组）。 I 组的缓解如下：11 例（39%）完全缓解，9 例（32%）部分缓解，2 例（7%）疾病稳定。第 2 组的缓解情况为：1 例（7%）完全缓解，2 例（14%）部分缓解，6 例（43%）疾病稳定。 I 患者 (7%) 因中性粒细胞减少症和肾毒性而发生治疗相关死亡。第 1 组的无进展生存期为 10 个月（范围为 4-19 个月）。截至分析时，57% 的患者在中位随访 10 个月（范围 4-21 个月）后仍存活。第 2 组的无进展生存期为 11 个月（范围，4-19 个月）。由于 3 级和 4 级血液学毒性，治疗调整如下：49 次（18%）和 18 次（19%）剂量减少（卡铂曲线下面积，2-3）、35 次（13%）和 14 次（15%）剂量延迟以及 8 次（3%）和 6 次剂量延迟第 I 组和第 2 组分别有 (6%) 治疗在第 8 天未给予油。结论：给予剂量密集 TC 后，未接受化疗的患者的缓解率为 71%。由于毒性而导致的治疗修改很频繁，但中性粒细胞减少性发热等严重并发症的发生率与其他报道的每 3 周治疗方案相似。
Objective: To evaluate the response of dose-dense paclitaxel/carboplatin (TC) patients with primarily advanced or recurrent endometrial cancer.Methods: Six courses of paclitaxel (90 mg/m(2)) and carboplatinum (area under the curve, 4) on days I and 8 every 3 weeks were administered. Response rates were evaluated according to the response evaluation criteria in solid tumors.Results: Dose-dense TC was administered to 42 patients. The median age was 63.9 years (range, 41-81 years). The main histopathologic types were serous/clear cell (n = 27) and endometrioid (n = 13). The patients were divided in 2 groups: chemotherapy-naive group (n = 28, group 1) and a group With previous chemotherapy (n = 14, group 2).The responses for group I were as follows: 11 (39%) complete response, 9 (32%) partial response, and 2 (7%) stable disease. The responses for group 2 were 1 (7%) complete response, 2 (14%) partial response, and 6 (43%) stable disease. Treatment-related death occurred in I patient (7%) because of neutropenia and nephrotoxicity.Progression-free survival for group 1 was 10 months (range, 4-19 months). At time of analysis, 57% of the patients were still alive after a median follow-up Of 10 months (range, 4-21 months). Progression-free survival for group 2 was 11 months (range, 4-19 months).Because of grades 3 and 4 hematologic toxicity, treatment adjustments were as follows: 49 (18%) and 18 (19%) dose reductions (carboplatin area under the Curve, 2-3), 35 (13%) and 14 (15%) dose delays, and 8 (3%) and 6 (6%) treatments were not administered oil day 8 for groups I and 2, respectively.Conclusions: Administration of dose-dense TC resulted in a response rate of 71% in chemotherapy-naive patients. Treatment modifications due to toxicity were frequent, but severe complications such as neutropenic fever Occurred in a similar incidence as other reported 3-weekly regimens.